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Efﬁcacy and safety of anti-PD-1/PD-L1 agents vs
chemotherapy in patients with gastric or
gastroesophageal junction cancer: a systematic
review and meta-analysis
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∗
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Abstract
Background: Current therapeutic options have limited efﬁcacy for patients with advanced gastric or gastroesophageal junction
cancer. Immune checkpoint inhibition now has been increasingly used in advanced gastric or gastroesophageal junction cancer
therapy. To further understand the efﬁcacy and safety of anti-programmed cell death 1 (PD-1) and its ligand 1 (PD-L1) agents is critical
for clinical practice. We conducted this systematic review and meta-analysis to assess the beneﬁt and risk of PD-1 and PD-L1
inhibitors.
Methods: The PubMed, EMBASE, Cochrane Library, and Web of Science online databases were searched up to Jun 16, 2019.
Primary outcomes were overall survival (OS), progression-free survival (PFS). Second outcomes were objective response rate (ORR),
disease control rate (DCR) and adverse events.
Results: Six studies were assessed for inclusion in the ﬁnal synthesis, of which 5 were eligible for meta-analysis. Compared with
chemotherapy, the pooled hazard ratio (HR) for OS and PFSwas, respectively, 1.01 (95% conﬁdence interval [CI]: 0.88–1.15, P= .93)
and 1.58 (95%CI: 1.38–1.81, P< .001) after treatment with PD-1/PD-L1 inhibitors. In patients treated with anti-PD-1/PD-L1 agents,
the pooled ORR was 9.9% (95% CI: 4.4%–15.5%) and the pooled DCR was 30.8% (95% CI: 21.8%–39.9%). Sub-analysis for
treatment related adverse events indicated that fatigue was the most common toxicity in anti-PD-1/PD-L1 therapy (incidence 10.6%,
95% CI: 5.6%–15.6%).
Conclusion: PD-1/PD-L1 inhibitors appear to improve the antitumor activity in advanced gastric or gastroesophageal junction
cancer patients. However, single-agent PD-1/PD-L1 inhibitor did not result in a relative improvement in OS and PFS compared with
chemotherapy in the treatment of patients with advanced gastric or gastroesophageal junction cancer. Further randomized clinical
trials are warranted to conﬁrm our ﬁndings.
Abbreviations: CI = conﬁdence interval, DCR = disease control rate, HR = hazard ratio, ORR = objective response rate, OS =
overall survival, PD-1 = programmed cell death 1, PD-L1 = programmed death-ligand 1, PFS = progression-free survival, PRISMA =
Preferred Reporting Items for Systematic Reviews and Meta-analyses, VEGFR2 = vascular endothelial growth factor 2.
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Highlights:
1. PD-1/PD-L1 inhibitors showed a similar overall survival
outcome in comparison with chemotherapy in the treatment of
patients with advanced gastric or gastroesophageal junction
cancer.
2. PD-1/PD-L1 inhibitors increased the risk of disease progres-
sion relative to chemotherapy in the treatment of patients with
advanced gastric or gastroesophageal junction cancer.
3. Anti-PD-1 therapy had higher response rates than anti-PD-L1
therapy for treating advanced gastric or gastroesophageal
junction cancer.
1. Introduction
Gastric or gastroesophageal junction cancer is the ﬁfth most
common cancer and the third most common cause of cancer
mortality worldwide.[1] Patients with newly diagnosed advanced
gastric or gastroesophageal junction cancer have a poor
prognosis, with approximately 1-year lifespan. Particularly,
patients with recurrent or refractory gastric or gastroesophageal
junction cancer have an even worse prognosis.[2–5]
Editor: Undurti N. Das.
The authors have no funding and conﬂicts of interests to disclose.
a Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of
Science and Technology, b Department of Dermatology, the First Hospital of
Wuhan, Wuhan, China, c Institute of Anatomy, University of Bern, CH-3012 Bern,
Switzerland.
∗
Correspondence: Bi-Cheng Wang, Cancer Center, Union Hospital, Tongji
Medical College, Huazhong University of Science and Technology, 1277 Jiefang
Avenue, Wuhan, China (e-mail: bcsnowell@163.com).
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is
permissible to download, share, remix, transform, and buildup the work provided
it is properly cited. The work cannot be used commercially without permission
from the journal.
How to cite this article: Wang BC, Zhang ZJ, Fu C, Wang C. Efﬁcacy and safety
of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or
gastroesophageal junction cancer: a systematic review and meta-analysis.
Medicine 2019;98:47(e18054).
Received: 22 July 2019 / Received in ﬁnal form: 16 October 2019 / Accepted:
22 October 2019
http://dx.doi.org/10.1097/MD.0000000000018054
Systematic Review and Meta-Analysis Medicine®
OPEN
1
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
68
98
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0
For advanced gastric or gastroesophageal junction cancer
patients, treatment with platinum and ﬂuoropyrimidine is the
standardﬁrst line therapy,with trastuzumabadded for patientswith
human epidermal growth factor 2 positive tumors.[6–10] The second
line treatment options for patients with disease progression include
docetaxel, paclitaxel, or irinotecan and the vascular endothelial
growth factor 2 (VEGFR2) monoclonal antibody ramucirumab
alone or in combination with paclitaxel.[11–16] At present, no
standard third-line therapy is available for patients whose disease
progresses after 2 or more lines of systemic therapy that have been
recommended by international treatment guidelines.[8,9,17,18] Thus,
new treatment options for patients with advanced gastric or
gastroesophageal junction cancer are urgently needed.
Immune checkpoint inhibitors such as programmed cell death 1
(PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors
have revolutionized cancer therapy in recent years.[19,20] Over-
expression of PD-L1 has been observed in 65% of gastric
cancer,[21] making blockage of PD-1/PD-L1 signaling pathway a
rational target inpatientswith gastric or gastroesophageal junction
cancer. Initial trial results have demonstrated the antitumor
activity and safety of immunotherapy in patientswith unresectable
advanced or recurrent gastric or gastroesophageal junction cancer
in single-arm studies or randomized clinical trials using placebo or
chemotherapy as the comparator. However, there is no consensus
on the role of PD-1/PD-L1 inhibitors in the treatment of advanced
gastric or gastroesophageal junction cancer.
We are interested in how treatment with anti-PD-1/PD-L1
agents compares with placebo/chemotherapy for the outcomes
and adverse events. Thus, we performed this meta-analysis to
integrate the beneﬁt and risk of the PD-1/PD-L1 inhibitors in
published clinical trials of gastric or gastroesophageal junction
cancer. The results of our analysis should provide useful guidance
for future research.
2. Methods
We conducted the meta-analysis in accordance with the Preferred
Reporting Items for Systematic Reviews andMeta-analyses guideline
(PRISMA).[22] The data used in the analysis were not original raw
data, but were based on the published clinical studies with ethical
approvals. Therefore, ethical approval was not necessary.
2.1. Search strategy and study selection
The search was done in the electronic databases PubMed,
Cochrane Library, Web of Science, and EMBASE to identify all
relevant records until Jun 16, 2019. Additionally, the search
terms, including “gastric cancer or gastroesophageal junction
cancer or gastric adenocarcinoma or gastroesophageal junction
adenocarcinoma”, “pembrolizumab or nivolumab or avelumab
or atezolizumab or durvalumab”, and “trial or clinical trial or
randomized clinical trial or randomized controlled trial”, were
used to identify relevant articles with no restriction on language.
The references of relevant published studies and review articles
were searched for more eligible trials. The search results were
uploaded into EndNote (http://endnote.com/) for further review.
2.2. Inclusion and exclusion criteria
Studies eligible for inclusion met all of the following criteria:
(1) prospective clinical trials in patients with gastric or
gastroesophageal junction cancer,
(2) participants in immunotherapy armwere treated with a single
anti-PD-1/PD-L1 agent,
(3) antitumor activity and safety data were available.
Conference abstracts were excluded due to the increase of
heterogeneity. For multiple publications that were identiﬁed
reporting on the same clinical study, the one with the most
complete publication data was eligible. Any discrepancies were
resolved by discussion.
2.3. Data extraction
Detailed reviews of full-text articles regarding trial name, study
design, drug used, number of patients, PD-L1 status, line of
chemotherapy, and survival outcomes were independently
performed by Bi-Cheng Wang and Chen Fu. The hazard ratios
(HR) of overall survival (OS) and progression-free survival (PFS),
objective response rate (ORR), disease control rate (DCR) and
safety data reporting in the studies and supplementary materials
were obtained from each eligible trial.
2.4. Statistical analysis
OS and PFS data from randomized controlled trials were assessed
by HR and 95% conﬁdence interval (CI). RevMan version 5.3
software (Cochrane Collaboration’s Information Management
System) was used to conduct this part meta-analyses. A ﬁxed-
effects model was used when the heterogeneity test showed no
statistical signiﬁcance (P ≥ .10, I2 50%). Otherwise, a random-
effects model was applied. P< .05 was considered statistically
signiﬁcant differences.
Pooled incidences of ORR, DCR, any-grade treatment related
adverse events, and grade ≥3 treatment related adverse events
were done using STATA statistical software (version 14.0). The
analyses were conducted in a Random-effects model. Statistical
heterogeneity among the studies was tested by the CochranQ chi-
square test and I2 statistic percentages. Low heterogeneity was
deﬁned as I2<50% or P< .10. Publication bias for small-study
effects was evaluated by egger test.
3. Results
3.1. Eligible studies and characteristics
Our search of the PubMed, EMBASE, Cochrane Library, and
Web of Science databases identiﬁed 388 relevant publications.
We then excluded 125 records after screening the titles and
abstracts. After eligibility assessment, a total of ﬁve clinical trials
involving were selected for inclusion in the systematic review,[23–
27] comprising three randomized controlled trial and 2 single arm
trials (Fig. 1). Patients with advanced gastric or gastroesophageal
junction cancer in single anti-PD-1/PD-L1 agent arm were
selected for ﬁnal meta-analysis. The characteristics of the eligible
studies were displayed in Table 1. The survival outcomes in the
selected studies were presented in Table 2.
3.2. Overall survival (OS)
OS data was available from 2 studies,[25,27] including 481
patients in the anti-PD-1/PD-L1 group and 482 patients in the
chemotherapy group. Forest plots showed that the anti-PD-1/PD-
L1 group had a similar risk of death compared to chemotherapy
group (hazard ratio [HR]: 1.01, 95% CI: 0.88–1.15, P= .93;
heterogeneity [H]: I2=26%, P= .25) (Fig. 2).
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3.3. Progression-free survival (PFS)
PFS data was extracted from the same 2 studies in the above
analysis. Forest plots showed that patients in the anti-PD-1/PD-
L1 group had a statistically signiﬁcant higher risk of disease
progression compared to the chemotherapy (HR: 1.58, 95% CI:
1.38–1.81, P< .001; H: I2=12%, P= .29) (Fig. 3).
3.4. Objective response rate (ORR)
The ORR data of advanced gastric or gastroesophageal
junction cancer patients treated with anti-PD-1/PD-L1 agents
were available from 5 studies including 900 patients
(Table 3). The pooled ORR was 9.9% (95% CI: 4.4%–
15.5%). However, the test of heterogeneity showed that the
heterogeneity was high (I2=88.9%, P< .001), and egger test
indicated that there was a publication bias (P= .069< .1). In the
subgroup analysis, the pooled ORR was 11.3% (95% CI:
9.0%–13.7) in anti-PD-1 group, and 2.2% (95% CI: 0.1%–
4.3%) in anti-PD-L1 group. These results suggested that PD-1
inhibitors might have a higher ORR than PD-L1 inhibitors in
the treatment of advanced gastric or gastroesophageal junction
cancer patients.
Figure 1. Flow chart of the study identiﬁcation process.
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Table 1
Characteristics of the eligible studies.
Trial Year Design Drug No. Patients Male PD-L1+ patients Age (mean, range) Dose Line
KEYNOTE-012 2016 Phase Ib Pembrolizumab 39 28 (71.8%) 36 (100%) 63.0 (33–78) 10 mg/kg, q2weeks 0+
KEYNOTE-059 2018 Phase II Pembrolizumab 259 198 (76.4%) 148 (57.1%) 62.0 (24–89) 200mg, q3weeks 2+
KEYNOTE-061 2018 Phase III Pembrolizumab PEM: 296
PAC: 296
PEM: 202 (68.2%)
PAC: 208 (70.3%)
PEM: 196 (66.2%)
PAC: 199 (67.2%)
PEM: 62.5 (54–70)
PAC: 60.0 (53–68)
200mg, q3weeks 1+
ATTRACTION-2 2017 Phase III Nivolumab NIV: 330
PLA: 163
NIV: 229 (69.4%)
PLA: 119 (73.0%)
NIV: 16/130 (12.3%)
PLA: 10/62 (16.1%)
NIV: 62.0 (54–69)
PLA: 61.0 (53-68)
3 mg/kg, q2weeks 2+
JAVELIN Gastric 300 2018 Phase III Avelumab AVE: 185
CHE: 186
AVE: 140 (75.7%)
CHE: 127 (68.3%)
AVE: 46 (29.3%)
CHE: 39 (24.4%)
AVE: 59.0 (29–86)
CHE: 61.0 (18-82)
10 mg/kg, q2weeks 2+
AVE=avelumab, CHE= chemotherapy, Dose=anti-PD-1/PD-L1 agents dose, PAC=paclitaxel, PLA=placebo, PEM=pembrolizumab, NIV=nivolumab.
Table 2
Summary of the outcomes in the selected studies.
Study Median follow-up (months) Median duration of response (months) Median PFS (months) Median OS (months)
KEYNOTE-012 10.8 (IQR: 3.5–14.0) 1.9 (IQR: 1.6–1.9) 1.9 (95% CI: 1.8–3.5) 11.4 (95% CI: 5.7–NRD)
KEYNOTE-059 5.8 (range: 0.5–21.6) 8.4 (range: >1.6–>17.3) 2.0 (95% CI: 2.0–2.1) 5.6 (95% CI: 4.3–6.9)
KEYNOTE-061 7.9 (IQR: 3.4–14.6) PEM: 18.0 (95% CI: 8.3-NRD)
PAC: 5.2 (95% CI: 3.2–15.3)
PEM: 1.5 (95% CI: 1.4–1.6)
PAC: 4.1 (95% CI: 3.2–4.2)
PEM: 6.7 (95% CI: 5.4–8.9)
PAC: 8.3 (95% CI: 7.7–8.8)
ATTRACTION-2 NIV: 8.87 (IQR: 6.57–12.37)
PLA: 8.59 (IQR: 5.65–11.37)
NIV: 9.53 (95% CI: 6.14–9.82)
PLA: NR
NIV: 1.61 (95% CI: 1.54–2.30)
PLA: 1.45 (95% CI: 1.45–1.54)
NIV: 5.26 (95% CI: 4.60–6.37)
PLA: 4.14 (95% CI: 3.42–4.86)
JAVELIN Gastric 300 AVE: 10.6 (range: 0.1–17.8)
CHE: 10.6 (range: 0.0–17.6)
NR AVE: 1.4 (95% CI: 1.4–1.5)
CHE: 2.7 (1.8–2.8)
AVE: 4.6 (95% CI: 3.6–5.7)
CHE: 5.0 (4.5–6.3)
AVE=avelumab, CI=conﬁdence interval, CHE= chemotherapy, IQR= interquartile range, NIV=nivolumab, NRD=not reached, NR=not reported, PAC=paclitaxel, PEM=pembrolizumab, PLA=placebo.
Figure 2. Forest plots of hazard ratios for overall survival in patients with gastric or gastroesophageal junction cancer between PD-1/PD-L1 inhibitor group and
chemotherapy group. CI = conﬁdence interval, I2 = index of heterogeneity, IV = Inverse Variance statistical method, Fix = Fixed effect analysis model.
Figure 3. Forest plots of hazard ratios for progression-free survival in patients with gastric or gastroesophageal junction cancer between PD-1/PD-L1 inhibitor
group and chemotherapy group.
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3.5. Disease control rate (DCR)
TheDCRdataof patients treatedwith anti-PD-1/PD-L1agentswere
available from four of 5 studies including748patients (Table 4).The
pooled DCR was 30.8% (95% CI: 21.8%–39.9%). Although the
heterogeneity was high (I2=85.1%, P< .001), no publication bias
was observed through egger test (P= .815> .1). In anti-PD-1 group,
the pooled DCR was 34.1% (95% CI: 23.9%–44.4%), an 11.9%
higher rate in comparison with anti-PD-L1 group.
3.6. Treatment related adverse events
Overall, 412 (48.6%) of 847 advanced gastric or gastroesopha-
geal junction cancer patients from 4 studies developed at least 1
any-grade adverse event, and 98 (11.6%) of 847 patients
developed at least one adverse event of grade ≥3.
The overall incidence of any-grade treatment related toxicities
was 50.8% (95%CI: 43.4%–58.2%). Subgroup analysis showed
that the incidence of any-grade treatment related toxicities was
similar between anti-PD-1 group and anti-PD-L1 group (52.1%
vs 48.9%) (Table 5).
The overall incidence of grade ≥3 treatment related toxicities
was 11.3% (95%CI: 8.9%–13.7%). In addition, patients in anti-
PD-1 group (12.0%, 95%CI: 9.3%–14.8%) had a slightly higher
incidence compared with patients in anti-PD-L1 group (9.2%,
95% CI: 5.1%–13.4%) in the subgroup analysis of grade ≥3
treatment related adverse events (Table 6).
The most frequent any-grade toxicities were fatigue (10.6%,
95%CI: 5.6%–15.6%), pruritus (9.2%, 95%CI: 6.9%–11.4%),
rash (6.9%, 95%CI: 4.2%–9.5%), hypothyroidism (6.4%, 95%
CI: 3.1%–9.7%), diarrhea (6.2%, 95% CI: 4.8%–7.7%),
decreased appetite (6.0%, 95% CI: 3.8%–8.2%), and nausea
(5.5%, 95% CI: 4.1%–6.9%) (Table 7). For grade ≥3 treatment
related toxicities, anemia (2.5%, 95%CI: 1.2%–3.8%)was most
common, followed by fatigue (1.3%, 95% CI: 0.3%–2.2%),
decreased appetite (0.9%, 95% CI: 0.2%–1.6%), diarrhea
(0.5%, 95% CI: 0.1%–1.0%), and nausea (0.5%, 95% CI: –
0.1% to 1.0%) (Table 8).
3.6.1. Publication bias. Owing to the small number of the
studies analyzed, publication bias was not assessed for OS and
PFS. In the results of egger test, publication bias was only
observed in the ORR analysis (P= .069< .1), whereas the
analyses of DCR (P= .815> .1), any-grade adverse events
(P= .259> .1), and grade ≥3 adverse events (P= .786> .1)
showed no publication bias.
Table 3
Pooled analysis of objective response rate.
Study n Incidence 95% CI
Anti-PD-1
KEYNOTE-012 36 22.2% 8.6%–35.8%
KEYNOTE-059 259 11.6% 7.7%–15.5%
KEYNOTE-061 152 9.9% 5.1%–14.6%
ATTRACTION-2 268 11.2% 7.4%–15.0%
Sub-total 715 11.3% 9.0%–13.7%
Sub-H: I2=0%, P= .414
Anti-PD-L1
JAVELIN Gastric 300 185 2.2% 0.1%–4.3%
Sub-total 185 2.2% 0.1%–4.3%
Sub-H: -
Total 900 9.9% 4.4%–15.5%
H: I2=88.9%, P< .001
Egger test, P= .069
CI= conﬁdence interval, H=heterogeneity, n=number of patients.
Table 4
Pooled analysis of disease control rate.
Study n Incidence 95% CI
Anti-PD-1
KEYNOTE-012 36 36.1% 20.4%–51.8%
KEYNOTE-059 259 27.0% 21.6%–32.4%
ATTRACTION-2 268 40.3% 34.4%–46.2%
Sub-total 563 34.1% 23.9%–44.4%
Sub-H: I2=81.4%, P= .005
Anti-PD-L1
JAVELIN Gastric 300 185 22.2% 16.2%–28.1%
Sub-total 185 22.2% 16.2%–28.1%
Sub-H: -
Total 748 30.8% 21.8%–39.9%
H: I2=85.1%, P< .001
Egger test, P= .815
CI= conﬁdence interval, H=heterogeneity, n=number of patients.
Table 5
Pooled analysis of any-grade adverse events.
Study n Incidence 95% CI
Anti-PD-1
KEYNOTE-012 39 66.7% 51.9%–81.5%
KEYNOTE-061 294 52.7% 47.0%–58.4%
ATTRACTION-2 330 42.7% 37.4%–48.1%
Sub-total 663 52.1% 41.5%–62.8%
Sub-H: I2=83.8%, P= .002
Anti-PD-L1
JAVELIN Gastric 300 184 48.9% 41.7%–62.8%
Sub-total 184 48.9% 41.7%–62.8%
Sub-H: -
Total 847 50.8% 43.4%–58.2%
H: I2=75.8%, P= .006
Egger test, P= .259
CI=conﬁdence interval, H=heterogeneity, n=number of patients.
Table 6
Pooled analysis of grade ≥3 adverse events.
Study n Incidence 95% CI
Anti-PD-1
KEYNOTE-012 39 12.8% 2.3%–23.3%
KEYNOTE-061 294 14.3% 10.3%–18.3%
ATTRACTION-2 330 10.3% 7.0%–13.6%
Sub-total 663 12.0% 9.3%–14.8%
Sub-H: I2=13.2%, P= .316
Anti-PD-L1
JAVELIN Gastric 300 184 9.2% 5.1%–13.4%
Sub-total 184 9.2% 5.1%–13.4%
Sub-H: -
Total 847 11.3% 8.9%–13.7%
H: I2=14.4%, P= .320
Egger test, P= .786
CI=conﬁdence interval, H=heterogeneity, n=number of patients.
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4. Discussion
Findings from our meta-analysis suggested that PD-1/PD-L1
inhibitors did not signiﬁcantly decrease the relative risk of death
compared with chemotherapy in patients with advanced gastric
or gastroesophageal junction cancer after at least 1 line of
standard chemotherapy. Moreover, anti-PD-1/PD-L1 immuno-
therapy signiﬁcantly increased 58% of the risk of disease
progression.
Promising activity and manageable safety of anti-PD-1/PD-L1
immunotherapy had already been demonstrated in patients
advanced gastric or gastroesophageal junction cancer. In the
single arm clinical trial KEYNOTE-059,[24] the ORR was 11.6%
(95% CI: 8.0%-16.1%) when patients were treated with
pembrolizumab, and PD-L1 positive cancer showed a higher
ORR relative to PD-L1 negative cancer (15.5% vs 6.4%).
Patients treated with pembrolizumab in the previous phase Ib
study KEYNOTE-012 had also an expectable overall response
rate (22%).[23] Accordingly, the Food and Drug Administration
(FDA) granted accelerated approval for pembrolizumab for the
treatment of patients with advanced or recurrent gastric or
gastroesophageal junction cancer.[28] Another anti-PD-1 agent,
nivolumab, exhibited a signiﬁcantly lower risk of death than
placebo, and prolonged the median OS from 4.14 months to 5.26
months.[26] These survival beneﬁts indicated that PD-1 inhibitors
might be new treatment options for heavily pretreated advanced
gastric or gastroesophageal junction cancer patients. However,
the median PFS was less than 2 months, making the physicians
and patients hard to choose immunotherapy.
In KEYNOTE-061 studies, the differences were carefully
analyzed between pembrolizumab and paclitaxel in patients with
previously treated, advanced gastric or gastroesophageal junc-
tion cancer.[25] In the overall population, pembrolizumab group
had a shorter median OS (6.7 months vs 8.3 months) and an
obviously shorter median PFS (1.5 months vs 4.1 months). Even
in the PD-L1 positive population, the median OS was 9.1 months
with pembrolizumab and 8.3 months with paclitaxel. The
authors still considered that pembrolizumab did not improve the
OS in comparison with paclitaxel. The lack of survival beneﬁts
with blockage of PD-1/PD-L1 therapy was consistent with
ﬁnding from JAVELIN Gastric 300 study.[27] These suggested
that PD-1/PD-L1 antagonists might not be superior to chemo-
therapy in the treatment of patients with pretreated and advanced
gastric or gastroesophageal junction cancer.
In our ﬁndings, patients treated with PD-1 inhibitors achieved
higher response rates compared with patients received PD-L1
inhibitors therapy in the overall population. When patients were
treatedwith pembrolizumabor nivolumab, theORRswere ranged
from 9.9% to 22.2%. The KEYNOTE-012 demonstrated the
highest ORR partly due to the earlier line of immunotherapy that
patients received. However, participants in JAVELIN Gastric 300
showed only 2.2% ORR, extremely low response rate relative to
other studies. To analyze the difference, we noticed that 16 of 130
(12.3%) patients in nivolumab arm and 10 of 62 (16.1%) patients
in placebo arm were detected as elevated expression of PD-L1.
Conversely, in post-hoc analysis of KEYNOTE-061, the treatment
effects were greater for patients whose tumor had high expression
levels of PD-L1 and for patients with microsatellite instability.
Thus, we speculated that advanced gastric or gastroesophageal
junction cancer patients with overexpressed PD-L1might be more
suitable for anti-PD-1/PD-L1 treatment.
Encouragingly, ATTRACTION-4 study reported that nivolu-
mab combined with S-1 plus oxaliplatin or capecitabine plus
oxaliplatin was well tolerated and demonstrated promising
efﬁcacy as the ﬁrst-line therapy for unresectable advanced or
recurrent gastric or gastroesophageal junction cancer.[29] The
median OS was over 13.9 months, and the median PFS was 9.7
months. In addition, the ORR was 65.8%, and the DCR was
84.2%. Compared with a single PD-1/PD-L1 inhibitor in our
selected studies, immunotherapy in combination with chemo-
therapy had higher efﬁcacy. The combination treatment strategy
might be a better choice for patients with advanced gastric or
gastroesophageal junction cancer in the future.
All eligible studies reported a manageable toxicity proﬁle.
Nonetheless, from the standpoint of patient counseling, several
results of treatment related adverse events should be vigilant.
Nearly 50.8% of patients with advanced gastric or gastroesopha-
geal junction cancer treated with anti-PD-1/PD-L1 agents
experienced at least one any-grade treatment related adverse
event, and 11.3% had at least one grade ≥3 adverse event.
Although the participants in the clinical trials were heavily
pretreated, the incidence of grade ≥3 adverse events was low and
symptomatic toxicities were observed equally in both anti-PD-1
and anti-PD-L1 groups. The three most common any-grade
treatment related adverse events were fatigue (10.6%), pruritus
(9.2%), and rash (6.9%). The 3most common grade≥3 treatment
related adverse events were anemia (2.5%), fatigue (1.3%), and
decreased appetite (0.9%). These numbers can be critically shared
with patients with advanced gastric or gastroesophageal junction
cancer before they begin anti-PD-1/PD-L1 therapy. Considering
the potential risks, clinical vigilance is warranted for early
recognition and intervention to prevent severe complications.
4.1. Limitations
This meta-analysis has several limitations. First, there were 3
randomized controlled trials, but only KEYNOTE-061 and
Table 7
Pooled sub-analysis of any-grade adverse events.
AEs Incidence 95% CI
Fatigue 10.6% 5.6%–15.6%
Pruritus 9.2% 6.9%–11.4%
Rash 6.9% 4.2%–9.5%
Hypothyroidism 6.4% 3.1%–9.7%
Diarrhea 6.2% 4.8%–7.7%
Decreased appetite 6.0% 3.8%–8.2%
Nausea 5.5% 4.1%–6.9%
Anemia 3.4 –0.0%–6.8%
Pneumonia 1.3% –1.0%–3.7%
AEs=adverse events, CI= conﬁdence interval.
Table 8
Pooled sub-analysis of grade ≥3 adverse events.
AEs Incidence 95% CI
Anemia 2.5% 1.2%–3.8%
Fatigue 1.3% 0.3%–2.2%
Decreased appetite 0.9% 0.2%–1.6%
Diarrhea 0.5% 0.1%–1.0%
Nausea 0.5% –0.1%–1.0%
Pneumonia 0.4% –0.1%–0.9%
Hypothyroidism 0.4% –0.3%–1.2%
AEs=adverse events, CI= conﬁdence interval.
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JAVELIN Gastric 300 studies were included in the comparison
analysis, because ATTRACTION-2 was designed as placebo
controlled study. The results of further researches, such as
KEYNOTE 181 and KEYNOTE 585, are worth awaited.
Second, although we had searched three PD-L1 inhibitors, no
publications of atezolizumab or durvalumab were eligible for
ﬁnal analysis. Third, publication bias was observed in ORR
analysis due to the small size of eligible studies. Despite these
limitations, this meta-analysis is a meaningful study of the
estimates of the efﬁcacy and safety of PD-1/PD-L1 inhibitors in
the treatment for advanced gastric or gastroesophageal junction
cancer patients.
5. Conclusions
For patients with advanced gastric or gastroesophageal junction
cancer, single anti-PD-1/PD-L1 inhibitor was not superior to
chemotherapy. Although not studied via meta-analysis, anti-PD-
1/PD-L1 therapy combined with traditional chemotherapy was
an effective therapeutic regimen. Because four of 5 studies
included in our meta-analysis were open-label or single arm
clinical trials, bias cannot be excluded.
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